Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Lipocine
Company facts
- Status
- NASDAQ LPCN
- Headquarters
- SALT LAKE CITY, X1
- Industry
- Pharmaceutical Preparations SIC 2834
- Fiscal year end
- 1231
- Links
- Filings · SEC · Quote · Yahoo
- Source
- SEC
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | −3 | 11 | 2 |
| Operating income | −18 | −1 | −10 |
| Net income | −16 | 0 | −10 |
| Total assets | 23 | 23 | 17 |
| Total liabilities | 3 | 2 | 3 |
| Total equity | 20 | 21 | 14 |
Unit: USD million · Consolidated statements · Source SEC 10-K/20-F
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
pharmaceutical filing citing a Hepatology Communications paper — Lipocine, 2020-09-21 · Readout case C032
Pharmaceutical regulatory filing citing a Hepatology Communications paper — Lipocine, 2020-08-03 · Readout case C028
Journal of Endocrinological Investigation paper cited in pharmaceutical regulatory filing — Lipocine, 2021-03-04 · Readout case C040
Pharmaceutical regulatory filing citing a Hepatology Communications paper — Lipocine, 2020-09-14 · Readout case C031
National R&D projects (NTIS)
No records
Korean patent filings (KIPRIS)
No records
Papers with affiliated authors (OpenAlex)
No records
Last updated 2026-09-21